ADC Therapeutics (ADCT) Set to Announce Quarterly Earnings on Thursday

ADC Therapeutics (NYSE:ADCT) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $17.41 million for the quarter, compared to analysts’ expectations of $19.06 million. During the same period last year, the firm earned ($0.58) EPS. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ADC Therapeutics Stock Performance

NYSE ADCT traded up $0.05 during mid-day trading on Tuesday, hitting $3.07. The stock had a trading volume of 171,692 shares, compared to its average volume of 632,504. The company has a 50 day simple moving average of $3.01 and a 200 day simple moving average of $3.35. ADC Therapeutics has a 52-week low of $0.36 and a 52-week high of $6.04.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ADCT. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research report on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price on shares of ADC Therapeutics in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.